| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| lixivaptan | vasopressin v2 receptor | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Congestive heart failure[MeSHID:D006333] Hyponatremia[MeSHID:D007010] Skin Diseases Infectious[MeSHID:D012874] |
5.09 | phase 3 | antagonist |
| lixivaptan | vasopressin v2 receptor | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Congestive heart failure[MeSHID:D006333] Hyponatremia[MeSHID:D007010] Skin Diseases Infectious[MeSHID:D012874] |
5.09 | phase 3 | unknown |
| lixivaptan | histidine decarboxylase | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Congestive heart failure[MeSHID:D006333] Hyponatremia[MeSHID:D007010] Skin Diseases Infectious[MeSHID:D012874] |
15.91 | phase 3 | unknown |
| click here to return to the previous page | ||||||||